Peptide Library / Detail
ARA-290
Half-life
Short (~20 minutes after SC; minutes after IV), with pharmacodynamic effects outlasting plasma exposure
Delivery
Subcutaneous injection (e.g., once daily in 28-day study designs); IV used in early PK work.
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
ARA-290 (cibinetide) is an 11–amino acid peptide engineered from erythropoietin’s helix-B that selectively activates the EPOR–CD131 ‘innate repair receptor’ to promote tissue protection, anti-inflammatory signaling, and small-fiber nerve repair without stimulating erythropoiesis.
Usage
Studied in small fiber neuropathy (e.g., sarcoidosis-associated and type 2 diabetes), ocular/ischemic injury models, and inflammatory conditions to evaluate symptom relief, nerve fiber regeneration, and improved metabolic/quality-of-life outcomes.
Mechanism of Action
Binds the EPOR–CD131 heteroreceptor (innate repair receptor), triggering JAK2/STAT and PI3K/Akt pathways while suppressing NF-κB–mediated inflammation; restores tissue homeostasis and supports small-fiber nerve regrowth.
Benefits(5)
- Reduces neuropathic pain and autonomic symptoms in SFN studies
- Improves quality-of-life measures
- Increases corneal small-fiber nerve density in clinical imaging
- Anti-inflammatory, cytoprotective effects without erythropoiesis
- Metabolic improvements noted in type 2 diabetes cohorts
Side Effects(3)
- Generally well tolerated in trials
- Mild injection-site reactions
- No meaningful changes in hematocrit/hemoglobin (non-erythropoietic)